Vialwirebiotech, curated
July 2, 2026, 5:30 AM
July 2, 2026
- 3:23 AM · Pharmaceutical Technology3:23 AMInocras, AimedBio team up for cancer treatments — Pharmaceutical Technology
- 1:00 AM · Bloomberg — Technology1:00 AMNovo Owner Backs Italy Fund to Spur Drug Startups Beyond Denmark — Bloomberg — Technology
July 1, 2026
- 11:31 PM · Nikkei Asia11:31 PMTakeda and Insilico strike AI-led drug discovery deal worth up to $600m — Nikkei Asia
- 12:00 PM · BioWorld12:00 PMIn 2nd deal of week, Ipsen buys Memo’s kidney transplant antibody — BioWorld
- 12:00 PM · BioWorld12:00 PMYes we Can-Fite PDAC; phase IIa results add momentum — BioWorld
- 12:00 PM · BioWorld12:00 PMHK biotech listings gain traction in Q2 with trio of June IPOs — BioWorld
- 12:00 PM · BioWorld12:00 PMSome clinical trials in China under US congressional scrutiny — BioWorld
- 12:00 PM · BioWorld12:00 PM‘Cool move’ by Zimmer part of med-tech’s tuck-in deals trend — BioWorld
- 11:30 AM · Drug Discovery World11:30 AMCHMP adopts positive opinion for severe alopecia treatment — Drug Discovery World
- 10:20 AM · Pharmaceutical Executive10:20 AM<![CDATA[Wegovy Now Available to Eligible Medicare Beneficiaries Through Medicare GLP-1 Bridge ]]> — Pharmaceutical Executive
- 10:00 AM · Pharmaceutical Executive10:00 AM<![CDATA[AlzeCure Pharma Enters $2.2 Billion Licensing and Collaboration Agreement with QuantumCell ApS]]> — Pharmaceutical Executive
- 9:59 AM · Drug Discovery World9:59 AMAWS supports Fleming Initiative in boost to AMR treatment — Drug Discovery World
- 9:57 AM · Pharmaceutical Technology9:57 AMSanofi aims for Nexviazyme approval in younger Pompe disease patients — Pharmaceutical Technology
- 9:18 AM · BioPharma Dive9:18 AMAbivax shares surge as worries subside over immune drug’s cancer risk — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMFlare Therapeutics to focus on AR-ON degrader FX-111 — BioWorld
- 9:00 AM · BioWorld9:00 AMMED-EL acquires gene therapy programs from Rescue Hearing — BioWorld
- 9:00 AM · BioWorld9:00 AMGrant supports Aptevo’s immunotherapy APVO-451 for solid tumors — BioWorld
- 9:00 AM · BioWorld9:00 AMTelum Therapeutics advances antimicrobials with series A funding — BioWorld
- 8:50 AM · Pharmaceutical Technology8:50 AMEAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s — Pharmaceutical Technology
- 7:38 AM · STAT News7:38 AMSTAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients — STAT News
- 6:00 AM · SCMP — Tech6:00 AMHow a ‘Chinese heart’ could get US blood pumping despite biotech decoupling — SCMP — Tech
- 5:53 AM · Pharmaceutical Technology5:53 AMUS FDA rejects approval of Unicycive’s kidney disease therapy — Pharmaceutical Technology
- 5:09 AM · Pharmaceutical Technology5:09 AMEAN 2026: following EU approval, AbbVie highlights Aquipta efficacy for acute migraine — Pharmaceutical Technology
- 3:32 AM · Pharmaceutical Technology3:32 AMEli Lilly and Innovent agree Verzenios commercialisation deal in China — Pharmaceutical Technology
June 30, 2026
- 6:48 PM · STAT News
- 5:50 PM · MIT Technology Review5:50 PMClaude Science is Anthropic’s newest flagship product — MIT Technology Review
- 4:57 PM · BioPharma Dive4:57 PMIpsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMVistagen's SAD slump: lead pherine, fasedienol, fails again — BioWorld
- 12:00 PM · BioWorld12:00 PMCorxel-Vincentage’s oral GLP-1 meets phase II obesity endpoints — BioWorld
- 12:00 PM · BioWorld12:00 PMOtsuka’s centanafadine scores in ADHD, comorbid anxiety trial — BioWorld
- 12:00 PM · BioWorld12:00 PMFDA clears first flight of Precheck Rx manufacturing pilot — BioWorld
- 10:22 AM · BioPharma Dive10:22 AMBeeline ups its Series A round for immune drug work — BioPharma Dive
- 9:48 AM · BioPharma Dive9:48 AMTop FDA gene and cell therapy regulator to step down — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMBlueprint Medicines reports new CDK4 degrader PROTACs — BioWorld
- 9:00 AM · BioWorld9:00 AMCDW reports in vivo results for LNP-LANFA — BioWorld
- 9:00 AM · BioWorld9:00 AMHzyg ligands disclosed in MSD patent — BioWorld
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMGensci-134: a long-acting growth hormone receptor agonist fusion protein — BioWorld
- 9:00 AM · BioWorld9:00 AMDeerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal — BioWorld
- 9:00 AM · BioWorld9:00 AMYaoya Technology identifies new KRAS G12D mutant inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMSmartbax raises additional funds to advance antibiotic pipeline — BioWorld
- 9:00 AM · BioWorld9:00 AMHexapharmatec identifies new TFEB inducers — BioWorld
- 8:00 AM · Drug Discovery World8:00 AMIpsen acquires Kartos Therapeutics in $450m deal — Drug Discovery World
- 7:00 AM · Drug Discovery World7:00 AMBII boosts cardiometabolic innovation with new UK base — Drug Discovery World
- 6:00 AM · Drug Discovery World6:00 AMFDA approves Phase IIb study of new erectile dysfunction treatment — Drug Discovery World
- 5:53 AM · Pharmaceutical Technology5:53 AMTalawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger — Pharmaceutical Technology